GlaxoSmithKline faces thousands of lawsuits based on severe Paxil withdrawal symptoms.
Paxil withdrawal symptoms include muscle spasms, extreme sensitivity to sound , zapping electric-shock sensations, tremors.
Other Paxil withdrawal symptoms may include dizziness, headaches, nausea, confusion, flu-like side effects, insomnia, irritability, diarrhea, flatulence, sweating, visual disturbances, and movement disorders. Paxil antidepressant washes out of the body more quickly than most other SSRIs. Hence, the effects of its absence in the brain can occur with literally dizzying speed.
In the late 1990s, clinical studies offered evidence that the symptoms associated with Paxil and Paxil withdrawal appeared more often in patients treated with Paxil than in patients treated with other SSRI drugs.
Paxil withdrawal symptoms can last anywhere from two to eight weeks and have been well documented in the media and explored in the medical community. It afflicts users who are reducing their dosage, have missed taking a few pills, or have stopped taking Paxil antidepressant altogether.
A Paxil lawsuit against GlaxoSmithKline charged the drug company with failing to warn the public about the dangers of Paxil withdrawal symptoms. GlaxoSmithKline, the manufacturer of the antidepressant Paxil, resolved the suit. The results were not announced. The outcome was described as a resolution rather than a settlement. The suit charged that Paxil causes serious withdrawal problems, resulting in a widespread societal problem when many people find that they are unable to stop taking Paxil, a subtle form of Paxil addiction.
As a result of the Paxil withdrawal suit, GlaxoSmithKline finally updated its Paxil label with a specific mention of the danger of Paxil withdrawal symptoms. The revised label uses the favorable term – discontinuation -- instead of withdrawal. Discontinuation is a euphemism for withdrawal used to circumvent the negative connotations associated with addiction, dependency, and withdrawal syndromes. By using the term discontinuation instead of withdrawal, GlaxoSmithKline obscures the potential severity of Paxil withdrawal symptoms.
According to the label and since the marketing of Paxil, other withdrawal symptoms have been reported in association with the discontinuation of the drug. These post-marketing reports include dizziness, sensory disturbances such as electric shock sensations, agitation, anxiety, nausea, and sweating. Yet, GlaxoSmithKline claims that the reactions reported since the start of marketing have no relationship to Paxil and are self-limiting.
Independent research has shown that aggressive behavior is especially likely to result when a drug causes or increases agitation and anxiety in patients already suffering from psychiatric disorders such as anxiety, depression, panic, stress, and obsessions or compulsions. Furthermore, there is a growing body of clinical and research literature demonstrating irritability and aggression during withdrawal from Paxil.
However, the updated label makes no mention of any danger of aggressive, violent, or suicidal behavior during Paxil withdrawal symptoms.
Would you like to contact a Paxil lawyer about your Paxil withdrawal symptoms?